Galapagos NV and Asinex Initiate Drug Discovery Collaboration

Galapagos NV, a genomics-based drug discovery company and Asinex, a worldwide leader in lead generation and optimization announce that they have initiated an integrated drug discovery collaboration in bone and joint diseases. The collaboration will result in a set of optimized leads for Galapagos' validated bone and joint disease drug targets. Financial details have not been disclosed. In the first phase of the collaboration, Galapagos' biologists will work closely with Asinex's medicinal chemists, using Asinex's computational chemistry expertise and proprietary chemical compound libraries to generate new leads for Galapagos' proprietary targets.

PrimeZone (http://www.primezone.com/newsroom/?d=78024)